Cannot Answer This Question Based on Available Evidence
The provided evidence does not address your specific question about comparing 1-day miconazole 1% versus 3-day clotrimazole 1% for superficial dermatophyte infections.
Why This Question Cannot Be Answered
The evidence provided focuses on entirely different clinical scenarios:
Onychomycosis (nail infections): The majority of guidelines 1, 2, 1, 2 discuss systemic oral antifungals (terbinafine, itraconazole, fluconazole) for nail infections, which require weeks to months of treatment—completely different from the 1-3 day topical regimens you're asking about.
Tinea capitis (scalp infections): One guideline 3 addresses scalp ringworm requiring oral therapy for weeks, not topical short-course treatment.
Sporotrichosis: Another guideline 4 discusses this specific fungal infection unrelated to common dermatophyte infections.
Vaginal candidiasis: The only study addressing short-duration therapy 5 compares single-dose versus 3-day clotrimazole for vaginal yeast infections, not skin dermatophyte infections.
What the Evidence Actually Shows
The one comparative study of miconazole versus clotrimazole 6 used prolonged treatment courses (evaluated over 12 weeks), not the 1-day versus 3-day regimens you're asking about. The FDA drug labels 7, 8 confirm these products exist but provide no comparative efficacy data for your specific question.
To properly answer your question, I would need:
- Randomized controlled trials directly comparing 1-day miconazole versus 3-day clotrimazole for superficial dermatophyte infections (tinea corporis, cruris, or pedis)
- Guidelines specifically addressing short-course topical antifungal regimens for skin infections
- Studies measuring clinical and mycological cure rates with these specific durations